EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Assessment of pharmacokinetics, safety, and tolerability following twice‐daily administration of molnupiravir for 10 days in healthy participants

Marian Iwamoto iD, Kelly E Duncan, Prachi K Wickremasingha, Tian Zhao, Maria V Liberti, Lieselotte Lemoine, Tatjana Decaesteker, Sylvie Rottey, Brian M Maas, Gillian Gillespie, S Aubrey Stoch

Clinical and Translational Science · 2023-10 · 16 (10) · 1947-1956

DOI: 10.1111/cts.13602 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, online erschienen am 08.08.2023. Verfasst von Marian Iwamoto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: Leukocytes, Mononuclear. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Molnupiravir is an orally administered, small‐molecule ribonucleoside prodrug of β‐D‐N4‐hydroxycytidine (NHC) that has demonstrated potent, broad‐spectrum preclinical activity against RNA viruses and has a high barrier to the development of resistance. A double‐blind, placebo‐controlled, phase I trial was conducted to evaluate the pharmacokinetics (PKs), safety, and tolerability of 10.5‐day administration of multiple doses of molnupiravir and its metabolites in healthy, adult participants. Participants were randomly assigned (3:1) to receive molnupiravir (400 mg [ n = 6], 600 mg [ n = 6], and 800 mg [ n = 12]) or matching placebo ( n = 8) every 12 h (q12h) for 10.5 days. Blood was collected to evaluate the PKs of NHC in plasma and of its active metabolite, NHC‐triphosphate (NHC‐TP), in peripheral blood mononuclear cells (PBMCs). Molnupiravir was generally well‐tolerated. All adverse events were mild or moderate in severity and none led to treatment discontinuation. No clinically meaningful dose‐related safety findings were observed. Mean time to maximal concentration was ~1.50 to 1.98 h for plasma NHC and ~4.00 to 8.06 h for PBMC NHC‐TP. Accumulation was minimal (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukocytes, MononuclearAdultHumansHealthy VolunteersHalf-LifeDouble-Blind MethodDose-Response Relationship, DrugCytidineHydroxylamines

Substanzen

molnupiravirCytidineHydroxylamines

Autor:innen und Institutionen

  • Merck & Co., Inc., Rahway, New Jersey, USA.
  • Ghent University Hospital, Ghent, Belgium.

ORCID-Profile: Marian Iwamoto

Zitieren

APA

Iwamoto, M., Duncan, K. E., Wickremasingha, P. K., Zhao, T., Liberti, M. V., Lemoine, L., Decaesteker, T., Rottey, S., Maas, B. M., Gillespie, G., & Stoch, S. A. (2023). Assessment of pharmacokinetics, safety, and tolerability following twice‐daily administration of molnupiravir for 10 days in healthy participants. Clinical and Translational Science, 16(10), 1947-1956. https://doi.org/10.1111/cts.13602

Vancouver

Iwamoto M, Duncan KE, Wickremasingha PK, Zhao T, Liberti MV, Lemoine L, et al. Assessment of pharmacokinetics, safety, and tolerability following twice‐daily administration of molnupiravir for 10 days in healthy participants. Clinical and Translational Science. 2023;16(10):1947-1956. doi:10.1111/cts.13602

BibTeX
@article{Iwamoto2023,
  author = {Iwamoto, Marian and Duncan, Kelly E and Wickremasingha, Prachi K and Zhao, Tian and Liberti, Maria V and Lemoine, Lieselotte and Decaesteker, Tatjana and Rottey, Sylvie and Maas, Brian M and Gillespie, Gillian and Stoch, S Aubrey},
  title = {Assessment of pharmacokinetics, safety, and tolerability following twice‐daily administration of molnupiravir for 10 days in healthy participants},
  journal = {Clinical and Translational Science},
  year = {2023},
  volume = {16},
  number = {10},
  pages = {1947--1956},
  doi = {10.1111/cts.13602}
}
Kostenlos starten →